...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European Journal of Histochemistry >Celecoxib treatment does not alter recruitment and activation of osteoclasts in the initial phase of experimental tooth movement
【24h】

Celecoxib treatment does not alter recruitment and activation of osteoclasts in the initial phase of experimental tooth movement

机译：塞来昔布治疗在实验性牙齿运动的初始阶段不会改变破骨细胞的募集和激活

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In a previous study, we reported that the short-term treatment with celecoxib, a non-steroidal anti-inflammatory drug (NSAID) attenuates the activation of brain structures related to nociception and does not interfere with orthodontic incisor separation in rats. The conclusion was that celecoxib could possibly be prescribed for pain in orthodontic patients. However, we did not analyze the effects of this drug in periodontium. The aim of this follow-up study was to analyze effects of celecoxib treatment on recruitment and activation of osteoclasts and alveolar bone resorption after inserting an activated orthodontic appliance between the incisors in our rat model. Twenty rats (400-420 g) were pretreated through oral gavage with celecoxib (50 mg/kg) or vehicle (carboxymethylcellulose 0.4%). After 30 min, they received an activated (30 g) orthodontic appliance, set not to cause any palate disjunction. In sham animals, the appliance was immediately removed after introduction. All animals received ground food and, every 12 h, celecoxib or vehicle. After 48 h, they were anesthetized and transcardiacally perfused through the aorta with 4% formaldehyde. Subsequently, maxillae were removed, post-fixed and processed for histomorphometry or immunohistochemical analyses. As expected, incisor distalization induced an inflammatory response with certain histological changes, including an increase in the number of active osteoclasts at the compression side in group treated with vehicle (appliance: 32.2±2.49 vs sham: 4.8 ± 1.79, P<0.05) and celecoxib (appliance: 31.0±1.45 vs sham: 4.6±1.82, P<0.05). The treatment with celecoxib did not modify substantially the histological alterations and the number of active osteoclasts after activation of orthodontic appliance. Moreover, we did not see any difference between the groups with respect to percentage of bone resorption area. Taken together with our previous results we conclude that short-term treatment with celecoxib can indeed be a therapeutic alternative for pain relieve during orthodontic procedures.
机译：在先前的研究中，我们报道了塞来昔布（一种非甾体类抗炎药，NSAID）的短期治疗可减弱与伤害感受有关的脑结构的激活，并且不会干扰大鼠正畸门齿的分离。结论是塞来昔布可以用于正畸患者的疼痛治疗。但是，我们没有分析这种药物在牙周中的作用。这项后续研究的目的是分析塞来昔布治疗在我们的大鼠模型的门齿之间插入激活的正畸矫治器后对破骨细胞募集和活化以及牙槽骨吸收的影响。用塞来昔布（50 mg / kg）或溶媒（羧甲基纤维素0.4％）经口管饲法对20只大鼠（400-420 g）进行预处理。 30分钟后，他们接受了激活的（30克）正畸矫治器，其设置不会引起任何颚分离。在假动物中，该器具在引入后立即被移除。所有动物均接受地面食物，每12小时接受塞来昔布或媒介物。 48小时后，将它们麻醉并用4％甲醛经主动脉经心灌注。随后，去除上颌骨，固定后进行组织形态测定或免疫组织化学分析。如预期的那样，切牙远侧切开术会引起炎症反应，并具有一定的组织学改变，包括媒介物治疗组受压侧活动性破骨细胞数量的增加（器具：32.2±2.49 vs假：4.8±1.79，P <0.05），以及塞来昔布（电器：31.0±1.45 vs假：4.6±1.82，P <0.05）。塞来昔布治疗在激活正畸矫治器后并未实质性改变组织学改变和活性破骨细胞的数量。此外，就骨吸收面积的百分比而言，我们没有看到两组之间的任何差异。结合我们先前的研究结果，我们得出结论，短期使用塞来昔布确实可以作为正畸手术期间缓解疼痛的替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号